Protective effects of ebselen (Ebs) and para-aminosalicylic acid (PAS) against manganese (Mn)-induced neurotoxicity

Toxicology and Applied Pharmacology

Volumn 258, Issue 3, 2012, Pages 394-402

  Marreilha dos Santos, A P ^a   Lucas, Rui L ^a   Andrade, Vanda ^a   Mateus, M Luísa ^a   Milatovic, Dejan ^b   Aschner, Michael ^b   Batoreu, M Camila ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ebselen; F 2 Isoprostanes; Mn neurotoxicity; Neuroprotection; Para aminosalicylic acid; Prostaglandin E 2

Indexed keywords

AMINOSALICYLIC ACID; EBSELEN; GLUTATHIONE; MANGANESE; NEUROPROTECTIVE AGENT; PROLACTIN; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; IN VIVO STUDY; MALE; MANGANISM; MOBILIZATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; REARING;

AMINOSALICYLIC ACID; ANIMALS; AZOLES; BEHAVIOR, ANIMAL; BIOLOGICAL MARKERS; BRAIN; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; MANGANESE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; ORGANOSELENIUM COMPOUNDS; OXIDATIVE STRESS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

RATTUS;

EID: 84855922137     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.12.003     Document Type: Article

References (97)

1. Agusti A., Cauli O., Rodrigo R., Llansola M., Hernández-Rabaza V., Felipo V. p38 MAP kinase is a therapeutic target for hepatic encephalopathy in rats with portacaval shunts. Gut. 2011, 60:1572-1579.
2. Al-Khatib I.M.H., Dokmeci I., Fujiwara M. Differential role of nucleus accumbens and caudate-putamen in mediating the effect of nomifensine and methamphetamine on ambulation and rearing of rats in the open-field test. Jpn. J. Pharmacol. 1995, 67(1):69-77.
3. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 1996, 97:2672-2679.
4. Aschner M. Manganese as a potential confounder of serum prolactin. Environ. Health Perspect. 2006, 114(8):A458.
5. Aschner M., Lukey B., Tremblay A. The Manganese Health Research Program (MHRP): status report and future research needs and directions. NeuroToxicology 2006, 27:733-736.
6. Aschner M., Au C., Benedetto A. Manganese transport in eukaryotes: the role of DMT1. NeuroToxicology 2008, 29:569-576.
7. Awas J.A., Soteriou M.C., Drougas J.G., Stokes K.A., Roberts L.J., Pinson C.W. Plasma prostaglandin E1 concentrations and hemodynamics during intravenous infusions of prostaglandin E1 in humans and swine. Transplantation 1996, 61:1624-1629.
8. Basu S. Fatty acid oxidation and isoprostanes: oxidative strain and oxidative stress. Prostaglandins Leukot Essent Fatty Acids 2010, 82:219-225.
9. Bhabak K.P., Mugesh G. Synthesis, characterization, and antioxidant activity of some ebselen analogues. Chem. Eur. J. 2007, 13:4594-4601.
10. Bowler R.M., Gysens S., Diamond E., Nakagawa S., Drezgic M., Roels H.A. Manganese exposure: neuropsychological and neurological symptoms and effects in welders. NeuroToxicology 2006, 27:315-326.
11. Chaudhry U.A., Zhuang H., Crain B.J., Doré S. Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease. Alzheimers Dement. 2008, 4(1):6-13.
12. Chen C., Bazan N.G. Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 Pyramidal Neurons. AJP - J.N. Physiol. 2005, 93:929-941.
13. Cimino P.J., Keene C.D., Breyer R.M., Montine K.S., Montine T.J. Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr. Med. Chem. 2008, 15(19):1863-1869.
14. Crossgrove J., Zheng W. Manganese toxicity upon overexposure. NMR Biomed. 2004, 17(8):544-553.
15. Daniel F., Seksik P., Cacheux W., Jian R., Marteau P. Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. Inflamm. Bowel Dis. 2004, 10(3):258-260.
16. Desole M.S., Esposito G., Migheli R., Fresu L., Sircana S., Zangani D., Miele M., Miele E. Cellular defence mechanisms in the striatum of young and aged rats subchronically exposed to manganese. Neuropharmacology 1995, 34(3):289-295.
17. Desole M.S., Esposito G., Migheli R., Sircana S., Delogu M.R., Fresu L., Miele M., de Natale G., Miele E. Gluthathione deficiency potentiates Manganese toxicity in rat striatum and brainstem and in PC12 cells. Pharmacol. Res. 1997, 36(4):285-292.
18. Dorman D.C., Struve M.F., Clewell H.J., Andersen M.E. Application of pharmacokinetic data to the risk assessment of inhaled manganese. NeuroToxicology 2006, 27:752-764.
19. Dringen R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 2000, 62:649-671.
20. Du Z., Ma T., Winterthun S., Kristiansen K., Frøyland L., Madsen L. β-oxidation modulates metabolic competition between eicosapentaenoic acid and arachidonic acid regulating prostaglandin E2 synthesis in rat hepatocytes-Kupffer cells. Biochim. Biophys. Acta 2010, 1801:526-536.
21. Dukhande V.V., Malthankar-Phatak G.H., Hugus J.J., Daniels C.K., Lai J.C. Manganese-induced neurotoxicity is differentially enhanced by glutathione depletion in astrocytoma and neuroblastoma cells. Neurochem. Res. 2006, 31:1349-1357.
22. Durand T., Bultel-Poncé V., Guy A., El Fangour S., Rossi J.C., Galano J.M. Isoprostanes and phytoprostanes: bioactive lipids. Biochimie 2011, 93(1):52-60.
23. Ellingsen D.G., Haug E., Gaarder P.I., Bast-Pettersen R., Thomassen Y. Endocrine and immunologic markers in manganese alloy production workers. Scand. J. Work Environ. Health 2003, 29(3):230-238.
24. Erikson K.M., Dorman D.C., Lash L.H., Dobson A.W., Aschner M. Airborne manganese exposure differentially affects end points of oxidative stress in an age and sex-dependent manner. Biol. Trace Elem. Res. 2004, 100(1):49-62.
25. Erikson K.M., Dobson A.W., Dorman D.C., Aschner M. Manganese exposure and induced oxidative stress in the rat brain. Sci. Total. Environ. 2004, 1:334-335.
26. Ewan R.C. Effect of selenium on rat growth, growth hormone and diet utilization. J. Nutr. 1976, 106(5):702-709.
27. Fernandez-Checa J.C., Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol. Appl. Pharmacol. 2005, 204(3):263-273.
28. Finkelstein Y., Milatovic D., Aschner M. Modulation of cholinergic systems by manganese. NeuroToxicology 2007, 28:1003-1014.
29. Gao H.M., Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29(8):357-365.
30. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 1999, 27(9-10):922-935.
31. Hawkes W.C., Keim N.L. Dietary selenium intake modulates thyroid hormone and energy metabolism in men. J. Nutr. 2003, 133:3443-3448.
32. Herin G.A., Du S., Aizenman E. The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site. J. Neurochem. 2001, 78:1307-1314.
33. Hewett S., Uliasz T.F., Vidwans A.S., Hewett J.A. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther. 2000, 293:417-425.
34. Hong L., Jiang W., Pan H., Jiang Y., Zeng S., Zheng W. Brain regional pharmacokinetics of p-aminosalicylic acid and its n-acetylated metabolite: effectiveness in chelating brain manganese. Drug Metab. Dispos. 2011, 39:1904-1909.
35. Hsieh Y.P., Lin C.L., Shiue A.L., Yin H., Morrow J.D., Hsu J.C., Hsieh T.C., Wei H.J., Yen H.C. Correlation of F4-neuroprostanes levels in cerebrospinal fluid with outcome of aneurysmal subarachnoid hemorrhage in humans. Free Radic. Biol. Med. 2009, 47:814-824.
36. Jones D.C., Miller G.W. The effects of environmental neurotoxicants on the dopaminergic system: a possible role in drug addiction. Biochem. Pharmacol. 2008, 76:569-581.
37. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. U S A. 1996, 93(6):2317-2321.
38. Kim E.A., Cheong H.K., Joo K.D., Shin J.H., Choi S.B., Kim M.O., Lee I.J., Kang D.M. Effect of occupational manganese exposure on the central nervous system of welders: 1H magnetic resonance spectroscopy and MRI findings. NeuroToxicology 2007, 28(2):276-283.
39. Kobayashi T., Ohta Y., Yoshino J. Preventive effect of ebselen on acute gastric mucosal lesion development in rats treated with compound. Eur. J. Pharmacol. 2011, 414(2-3):271-279.
40. Ladefoged O., Roswall K., Larsen J.J. Acetone potentiation and influence on the reversibility of 2,5-hexanedione-induced neurotoxicity studied with behavioral and morphometric methods in rats. Pharmacol. Toxicol. 1994, 74:294-299.
41. Liao S.L., Ou Y.C., Chen S.Y., Chiang A., Chen C.J. Induction of cyclooxygenase-2 expression by manganese in cultured astrocytes. Neurochem. Int. 2007, 50:905-915.
42. Lu S.C. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999, 13:1169-1183.
43. Lucchini R., Albini E., Placidi D., Alessio L. Mechanism of neurobehavioral alteration. Toxicol. Lett. 2000, 112-113:35-39.
44. Macrae I.M., Takasago T., Peters E.E., Graham D.I., Masayasu H. Neuroprotective eficacy of ebselen, an anti-oxidant with anti- inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. 1997, 122:1251-1256.
45. Maeda H., Sato M., Yoshikawa A., Kimura M., Sonomura T., Terada M., Kishi K. Brain MR imaging in patients with hepatic cirrhosis: relationship between high intensity signal in basal ganglia on T1-weighted images and elemental concentrations in brain. Neuroradiology 1997, 39(8):546-550.
46. Malecki E.A. Manganese toxicity is associated with mitochondrial dysfunction and DNA fragmentation in rat primary striatal neurons. Brain Res. Bull. 2001, 55(2):225-228.
47. Markoe R.C.L. The use of para-amino salicylic acid in the treatment of tuberculosis. J. Natl. Med. Assoc. 1950, 42(6):364-366.
48. Marreilha dos Santos A.P., Santos D., Au C., Milatovic D., Aschner M., Batoréu M.C. Antioxidants prevent the cytotoxicity of manganese in RBE4 cells. Brain Res. 2008, 21(1236):200-205.
49. Marreilha dos Santos A.P., Lopes Santos M., Batoreu M.C., Aschner M. Prolactin is a peripheral marker of manganese neurotoxicity. Brain Res. 2011, 1382:282-290.
50. Mãrtensson J., Meister A. Glutathione deficiency decreases tissue ascorbate levels in newborn rats: ascorbate spares glutathione and protects. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:4656-4660.
51. Masa E., Michel F., Guyb A., Bultel V., Falquetc Y., Chardonc P., Rossi J.C., Cristol J.P., Durand T. Quantification of urinary F2-isoprostanes with 4(RS)-F4t-neuroprostane as an internal standard using gas chromatography-mass spectrometry. Application to polytraumatized patients. J. Chromatogr. 2008, 872(1-2):133-140.
52. Matsumura K., Kobayashi S. Signaling the brain in inflammation: the role of endothelial cells. Front. Biosci. 2004, 9:2819-2826.
53. Meeker J.D., Rossano M.G., Protas B., Diamond M.P., Puscheck E., Daly D., Paneth N., Wirth J.J. Multiple metals predict prolactin and thyrotropin (TSH) levels in men. Environ. Res. 2009, 109:869-873.
54. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 1983, 52:711-760.
55. Milatovic D., Aschner M., 2009. Measurement of isoprostanes as markers of oxidative stress in neuronal tissue. Curr. Protocol. Toxicol. 12.14, 1-12.
56. 4-neuroprostanes from excitotoxicity and innate immune response in vivo by α-or γ-tocopherol. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 827(1):88-93.
57. Milatovic D., Yin Z., Gupta R.C., Sidoryk M., Albrecht J., Aschner J.L., Aschner M. Manganese induces oxidative impairment in cultured rat astrocytes. Toxicol. Sci. 2007, 98(1):198-205.
58. Milatovic D., Milatovic S.Z., Gupta R.C., Yu Y., Aschner M. Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol. Appl. Pharmacol. 2009, 240:219-225.
59. Miller S.B. Prostaglandins in health and disease: an overview. Semin. Arthritis Rheum. 2006, 36(1):37-49.
60. Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts L.J., Morrow J.D., Montine T.J. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids 2004, 128:117-124.
61. Moreno J.A., Streifel K.M., Sullivan K.A., Hanneman W.H., Tjalkens R.B. Manganese-induced NF-κB activation and nitrosative stress is decreased by estrogen in juvenile mice. Toxicol. Sci. 2011, 122(1):121-133.
62. Morrow J.D., Roberts L.J. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol. 1999, 300:3-12.
63. Myers J.E., Thompson M.L., Naik I., Theodorou P., Esswein E., Tassell H. The utility of biological monitoring for manganese in ferroalloy smelter workers in South Africa. NeuroToxicology 2003, 24(6):875-883.
64. Nakamura Y., Feng Q., Kumagai T., Torikai K., Ohigashi H., Osawa T., Noguchi N., Niki E., Uchida K. Ebselen, a glutathione peroxidase mimetic seleno-organic compound, as a multifunctional antioxidant. Implication for inflammation-associated carcinogenesis. J. Biol. Chem. 2002, 277(4):2687-2694.
65. Nelson M., Huggins T., Licorish R., Carroll M.A., Catapane E.J. Effects of p-aminosalicylic acid on the neurotoxicity of manganese on the dopaminergic innervation of the cilia of the lateral cells of the gill of the bivalve Crassostrea virginica mollusk. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2010, 151:264-270. (C).
66. Parnham M., Sies H. Ebselen: prospective therapy for cerebral ischaemia. Expert Opin. Investig. Drugs 2000, 9:607-619.
67. Portanova J.P., Zhang Y., Anderson G.D., Hauser S.D., Masferrer J.L., Seibert K., Gregory S.A., Isakson P.C. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia and interleukin 6 production in vivo. J. Exp. Med. 1996, 184(3):883-891.
68. Praticò D., Lawson J.A., Rokach J., FitzGerald G.A. The isoprostanes in biology and medicine. Trends Endocrinol. Metab. 2001, 12(6):243-247.
69. Ranasinghe J.G., Liu M.C., Sakakibara Y., Suiko M. Manganese administration induces the increased production of dopamine sulfate and depletion of dopamine in Sprague-Dawley rats. J. Biochem. 2000, 128(3):477-480.
70. Rattanakul C., Lenbury Y. A mathematical model of prolactin secretion: effects of dopamine and thyrotropin-releasing hormone. Math. Comput. Model. 2009, 49:1883-1892.
71. 2-Isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 2000, 4(28):505-513.
72. Rosa D.M., Roesler R., Braga A.L., Saffi J., Henriques J.A.P. Pharmacology and toxicology of diphenil disselenide in several biological models. Braz. J. Med. Biol. Res. 2007, 40:1287-1304.
73. Saad S.Y., Najjar T.A., Arafah M.M. Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats. Basic Clin. Pharmacol. Toxicol. 2006, 99:412-417.
74. Sadek A.H., Rauch R., Schulz P.E. Parkinsonism due to manganism in a welder. Int. J. Toxicol. 2003, 22:393-401.
75. Saldívar-González J.A., Campos-Rodriguez U.E., Cano-Cruz M.A. Differential effect of clozapine and haloperidol on rats treated with methylphenidate in the open field test. Proc. West. Pharmacol. Soc. 2009, 52:63-66.
76. Salom J.B., Pérez-Asensio F.J., Burguete M.C., Maŕin N., Pitarch C., Torregrosa G., Romero F.J., Alborch E. Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. Eur. J. Pharmacol. 2004, 495(1):55-62.
77. Santamaria A.B. Manganese exposure, essentiality & toxicity. Indian J. Med. Res. 2008, 128:484-500.
78. Santos, M. L., 2008. Study of biomarkers to evaluate the protective effects of antioxidants against manganese neurotoxicity. Dissertation of Master Thesis in Environment and Human Biology. Faculty of Sciences, University of Lisbon.
79. Satoh T., Ishige K., Sagara Y. Protective effects on neuronal cells of mouse afforded by ebselen against oxidative stress at multiple steps. Neurosci. Lett. 2004, 371:1-5.
80. Sriram K., Lin G.X., Jefferson A.M., Roberts J.R., Chapman R.S., Chen B.T., Soukup J.M., Ghio A.J., Antonin J.M. Dopaminergic neurotoxicity following pulmonary exposure to manganese-containing welding fumes. Arch. Toxicol. 2010, 84(7):521-540.
81. Stredrick D.L., Stokes A.H., Worst T.J., Freeman W.M., Johnson E.A., Lash L.H., Aschner M., Vrana K.E. Manganese-induced cytotoxicity in dopamine-producing cells. NeuroToxicology 2004, 25(4):543-553.
82. Takser L., Mergler D., de Grosbois S., Smargiassi A., Lafond J. Blood manganese content at birth and cord serum prolactin levels. Neurotoxicol. Teratol. 2004, 26:811-815.
83. Tanaka M., Takezawa N., Kumai T., Watanabe M., Matsumoto N., Nakaya S., Kobayashi S. Ebselen protects against the reduction in levels of drug-metabolizing enzymes in livers of rats with deoxycholic acid-induced liver injury. Pharmacol. Toxicol. 2002, 91(2):64-70.
84. Tapina D., Kennedy G., Lambert J., Zayeda J. Bioaccumulation and locomotor effects of manganese sulfate in Sprague-Dawley rats following subchronic (90days) inhalation exposure. Toxicol. Appl. Pharmacol. 2006, 211:166-174.
85. Vezér T., Kurunczi A., Náray M., Papp A., Nagymajtényi L. Behavioral effects of subchronic inorganic manganese exposure in rats. Am. J. Ind. Med. 2007, 50(11):841-852.
86. Wendeburg L., Pinheiro de Oliveira A.C., Bhatia H.S., Candelario-Jalil E., Fiebich B.L. Resveratrol inhibits prostaglandin formation in IL-1β-stimulated SK-N-SH neuronal cells. J. Neuroinflammation 2009, 6:26.
87. Wetli H.A., Buckett P.D., Wessling-Resnick M. Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem. Biol. 2006, 13:965-972.
88. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993, 11:371-386.
89. Yamaguchi T., Sano K., Takakura K., Saito I., Shinohara Y., Asano T., Yasuhara H. Ebselen in acute ischemic stroke a placebo-controlled, double-blind clinical trial. Stroke 1998, 29:12-17.
90. Yang S.Y., Gao Z.X. Determination and clinical significance of plasma levels of prostaglandins in patients with acute brain injury. Surg. Neurol. 1999, 52(3):238-245.
91. Yin Z., Aschner J.L., dos Santos A.P., Aschner M. Mitochondrial-dependent manganese neurotoxicity in rat primary astrocyte cultures. Brain Res. 2008, 8(1203):1-11.
92. Yoon H., Kim D.S., Lee G.H., Kim J.Y., Kim D.H., Kim K.W., Chae S.W., You W.H., Lee Y.C., Park S.J., Kim H.R., Chae H.J. Protective effects of sodium para-amino salicylate on manganese-induced neuronal death: the involvement of reactive oxygen species. J. Pharm. Pharmacol. 2009, 61(11):1563-1569.
93. Yoshida M., Iizuka K., Terada A., Hara M., Nishijima H., Akinori Shimada, Nakada K., Satoh Y., Akama Y. Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats. Tohoku J. Exp. Med. 2000, 191(4):209-220.
94. 4-Neuroprostanes. Free Radic. Biol. Med. 2003, 12(34):1631-1635.
95. Zhang S., Fu J., Zhou Z. In vitro effect of manganese chloride exposure on reactive oxygen species generation and respiratory chain complexes activities of mitochondria isolated from rat brain. Toxicol. In Vitro 2004, 18:71-77.
96. Zhao R., Masayasu H., Holmgren A. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8579-8584.
97. Zheng W., Jiang Y.M., Zhang Y., Jiang W., Wang X., Cowan D.M. Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats. NeuroToxicology 2009, 30:240-248.